LCB 04A
Alternative Names: LCB-04ALatest Information Update: 08 Jan 2025
At a glance
- Originator LegoChem Biosciences
- Developer LigaChem Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 17 Dec 2021 LCB 04A is available for licensing as of 17 Dec 2021. https://www.legochembio.com/rnd/partners.php?lang=e
- 17 Dec 2021 Early research in Haematological malignancies in South Korea (Parenteral) LegoChem Biosciences pipeline, December 2021)
- 17 Dec 2021 Early research in Solid tumours in South Korea (unspecified route) (LegoChem Biosciences pipeline, December 2021)